Vor Biopharma Inc. (VOR)
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vor Biopharma Inc.
1-25 of 461 filings
Recent SEC filings with analysis
- 424B5Vor Biopharma entered into a $150 million at-the-market offering agreement with William Blair and RBC Capital Markets dated October 30, 2026, replacing its…
- 10-QVor Biopharma reported a Q3 2026 net loss of $86.7 million and nine-month net loss of $369.1 million, with $481.6 million in cash, cash equivalents and…